SCHEMBL1688374

SCHEMBL1688374

O=Cc1ccc2cc(N3CCCCC3)ccc2c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.68
SMN1; SMN2 Q16637 2/20 0.68
KDM4E B2RXH2 1/20 0.68
TRIM24 O15164 1/20 0.65
TRIM33 Q9UPN9 1/20 0.65
ALDH1A3 P47895 5/20 0.53
TERT O14746 2/20 0.50
MAPT P10636 3/20 0.45
ACHE P22303 2/20 0.44
APP P05067 1/20 0.44
PTGS2 P35354 2/20 0.44
ABL1 P00519 1/20 0.43
MEN1 O00255 1/20 0.42
LMNA P02545 1/20 0.42
S100B P04271 1/20 0.42
GAA P10253 1/20 0.42
PKM P14618 1/20 0.42
ALOX15 P16050 1/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29663202 1.00 ALDH1A1 (0.68) ALDH1A1SMN1; SMN2KDM4ETRIM24TRIM33
SCHEMBL24988105 0.98 TRIM24 (0.67) ALDH1A1SMN1; SMN2KDM4ETRIM24TRIM33
SCHEMBL30343620 0.98 TRIM24 (0.67) ALDH1A1SMN1; SMN2KDM4ETRIM24TRIM33
SCHEMBL24989604 0.95 TRIM24 (0.61) ALDH1A1SMN1; SMN2KDM4ETRIM24TRIM33
SCHEMBL30343617 0.95 TRIM24 (0.61) ALDH1A1SMN1; SMN2KDM4ETRIM24TRIM33
SCHEMBL2013869 0.83 ALDH1A1 (0.70) ALDH1A1SMN1; SMN2KDM4ETRIM24TRIM33
SCHEMBL31611878 0.83 HTR3E (0.63) ALDH1A1SMN1; SMN2KDM4ETRIM24TRIM33
SCHEMBL1688379 0.83 ALDH3A1 (0.56) ALDH1A1SMN1; SMN2KDM4ETRIM24TRIM33
SCHEMBL160596 0.81 ALDH1A1 (1.00) ALDH1A1SMN1; SMN2KDM4ETRIM24TRIM33
SCHEMBL896372 0.81 ALDH1A1 (1.00) ALDH1A1SMN1; SMN2KDM4ETRIM24TRIM33

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4652155-A1 AMYLOID TARGETING AGENTS Amydis, Inc. (US) 2025-11-26 EP disclosed
US-12478693-B2 Compositions and methods for detection of traumatic brain injury Amydis, Inc. (US) 2025-11-25 US disclosed
US-20250282723-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2025-09-11 US disclosed
US-20250213732-A1 PHOSPHATE COMPOUNDS FOR DETECTING NEUROLOGICAL DISORDERS AMYDIS INC (US) 2025-07-03 US disclosed
EP-4545518-A2 PHOSPHATE COMPOUNDS FOR DETECTING NEUROLOGICAL DISORDERS Amydis, Inc. (US) 2025-04-30 EP disclosed
US-20240325572-A1 N-HETEROCYCLYL SUBSTITUTED 2-CYANO-3-(NAPHTHALEN-2-YL)ACRYLAMIDE DERIVATIVES AS FLUOROPHORS FOR DETECTION OF AMYLOID AND AMYLOID-LIKE PROTEINS FOR DIAGNOSIS OF NEURODEGENERATIVE DISORDERS Amydis, Inc. 2024-10-03 US disclosed
WO-2024155678-A1 AMYLOID TARGETING AGENTS Amydis, Inc. (US) 2024-07-25 WO disclosed
EP-3873466-B1 PHOSPHATE COMPOUNDS FOR DETECTING NEUROLOGICAL DISORDERS AMYDIS INC (US) 2024-07-24 EP disclosed
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2024-06-27 US disclosed
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2024-06-27 US disclosed
EP-3062150-A2 CHEMICALLY AMPLIFIED POSITIVE RESIST COMPOSITION AND PATTERN FORMING PROCESS Shin-Etsu Chemical Co., Ltd. (JP) 2016-08-31 EP disclosed
WO-2015143185-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME AMYDIS DIAGNOSTICS (US) 2015-09-24 WO disclosed
WO-2015143185-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME AMYDIS DIAGNOSTICS (US) 2015-09-24 WO disclosed
US-20150177262-A1 AMYLOID BINDING AGENTS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-06-25 US disclosed
EP-2509940-B1 AMYLOID BINDING AGENTS UNIV CALIFORNIA (US) 2015-06-10 EP disclosed
US-8940918-B2 Amyloid binding agents THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-01-27 US disclosed
US-20120302603-A1 AMYLOID BINDING AGENTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-11-29 US disclosed
EP-2509940-A2 AMYLOID BINDING AGENTS The Regents of the University of California (US) 2012-10-17 EP disclosed
US-20120088746-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME PFIZER INC. (US) 2012-04-12 US disclosed
WO-2011072257-A2 AMYLOID BINDING AGENTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302603-A1 AMYLOID BINDING AGENTS APP, APBA1, PSEN1 ALDH1A1 3897/4885SMN1; SMN2 355/4885KDM4E 4814/4885
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 ALDH1A1 4151/4885SMN1; SMN2 1194/4885KDM4E 4807/4885
US-12478693-B2 Compositions and methods for detection of traumatic brain injury S100B, FABP7, CRYAB ALDH1A1 4102/4885SMN1; SMN2 1319/4885KDM4E 4796/4885
US-20250282723-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME CRYAA, IAPP, APP ALDH1A1 4174/4885SMN1; SMN2 964/4885KDM4E 4812/4885
US-20120088746-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME TRPV1, TRPA1, TRPV2 ALDH1A1 1265/4885SMN1; SMN2 2207/4885KDM4E 4075/4885
US-20250213732-A1 PHOSPHATE COMPOUNDS FOR DETECTING NEUROLOGICAL DISORDERS PYGB, PSEN2, PSEN1 ALDH1A1 4527/4885SMN1; SMN2 86/4885KDM4E 4579/4885
US-20240325572-A1 N-HETEROCYCLYL SUBSTITUTED 2-CYANO-3-(NAPHTHALEN-2-YL)ACRYLAMIDE DERIVATIVES AS FLUOROPHORS FOR DETECTION OF AMYLOID AND AMYLOID-LIKE PROTEINS FOR DIAGNOSIS OF NEURODEGENERATIVE DISORDERS TARDBP, CDR2, NLN ALDH1A1 2727/4885SMN1; SMN2 305/4885KDM4E 4591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.